BCR-ABL MUTATIONS IN CHRONIC MYELOID LEUKEMIA TREATED WITH TYROSINE KINASE INHIBITORS - IMPACT ON SURVIVAL ? A STUDY ON BEHALF OF LATIN AMERICAN LEUKEMIA NET

LOPEZ, JL, BENDIT, I, PAGNANO K, HOKAMA P, ZALBERG I, PEREIRA N, GIERI I, LARRIPA I, GUEVARA G, ORDUZ R; BENDIT I; BOQUIMPONI C; DE SOUZA C; MIRANDA E; ZALCKERG I; LARRIPA I.; NADINELLI L; SILVEIRA R; FOGLIATTO L; FUNKE V; PASQUINI R; HUNGRIA V; CHIATTONE C; CLEMENTINO N; CONCHON M; MOIRAGHI B; VARELA A; LOPEZ J; PAVLOVSKY C; MAGARIÑOS A; FANILLA E; CORTES J; BENGIO R

CANCER INVESTIGATION

TAYLOR & FRANCIS INC

Lugar: Abingdon, Oxford; Año: 2015 vol. 33 p. 451 - 458

0735-7907

AbstractThis is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent mutation was T315I (n = 31, 16%). Progression-free (PFS) and overall survival (OS) at 5 years were lower in patients with BCR-ABL mutations (43% vs. 65%, p = 0.07 and 47% vs. 72%, p = 0.03, respectively) and in those with the T315I mutation (p = 0.003 and p = 0.03). OS and PFS were superior in subgroup who switched to second generation inhibitors (SGIs) after IM failure (OS: 50% vs. 39% p = 0.01; PFS: 48% vs. 30% p = 0.02). BCR-ABL mutations conferred a significant poor prognosis in CML patients